CD40LG and autoimmune thrombocytopenic purpura: Therefore, in ITP, it is likely that rituximab exerts its immunomodulatory effects through other mechanisms, e.g. IgM positive B cells, an influence on T cell balance47, the induction of regulatory B cells48, or simply through reduction of anti-platelet antibodies in ITP5.